Clinical trials: HBV Reactivation
Hepatitis B
A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy
Liver diseases due to hepatitis B reactivation are serious causes of morbidity and mortality in hepatitis B infected patients treated with chemotherapy.
- Trial name
- NCT00489151
- Testing
- adefovir dipivoxil, lamivudine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hospital Authority, Hong Kong
Lymphoma
Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP
The aim of this study is to identify the incidence of hepatitis B virus reactivation rate in Diffuse Large B Cell or high grade Follicular lymphoma patients with prior resolved hepatitis B undergoing RCHOP immuno-chemotherapy.
- Trial name
- IHBVRL (NCT01210287)
- Testing
- nucleoside analog reverse transcriptase inhibitor
- Where
- 2 sites in China
- Volunteers
- 110 people
- Sponsor
- Fudan University
Hepatitis B Reactivation
HBV Vaccine in Anti-core Positive Donors After LT
Anti-HBc positive liver donors frequently have occult HBV infection, and several studies in HBsAg-negative subjects have shown that there is often the detection in the liver of covalently closed circular DNA (cccDNA).
- Trial name
- NCT04442841
- Testing
- Hepatitis B vaccine
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatitis B, Hepatocellular Carcinoma
The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma
This study aim to find out the risk of exacerbation of chronic hepatitis B after percutaneous radiofrequency ablation (RFA) or hepatectomy for HCC, and it's effect to treatment outcome.
- Trial name
- HBV-HCC (NCT00720668)
- Testing
- radiofrequency ablation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Spontaneous Reactivation of Hepatitis B
To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B
The relevant data will be prospectively collected included patient demographics, clinical, all laboratory variables including virological tests, genotyping by direct sequencing, abdominal ultrasound, and upper gastrointestinal…
- Trial name
- NCT01732224
- Testing
- Tenofovir + Telbivudine, Tenofovir
- Where
- India
- Volunteers
- 69 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
COVID-19 Pneumonia, Hypoxemia
Hepatitis B Virus Reactivation in COVID-19
The aim of this observational cohort study was to evaluate adherence to hepatitis B virus (HBV) screening guidelines in a country characterized by low HBV prevalence and assess the potential reactivation and progression of HBV…
- Conditions
- COVID-19 Pneumonia, Hypoxemia, Hepatitis B
- Trial name
- HBV-C19 (NCT07154212)
- Testing
- Hepatitis B virus infection
- Where
- Slovenia
- Volunteers
- 1,793 people
- Sponsor
- University Medical Centre Ljubljana
Hepatitis B, Lymphoma
Tenofovir to Prevent HBV Reactivation
The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's…
- Conditions
- Hepatitis B, Lymphoma, Non-Hodgkin
- Trial name
- NCT02186574
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Canada
- Volunteers
- 184 people
- Sponsor
- University Health Network, Toronto
Hepatitis B Reactivation
TAF to Prevent HBV Reactivation in Cancer Patients
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing.
- Trial name
- NCT04619082
- Testing
- Tenofovir alafenamide
- Where
- 5 sites in Taiwan
- Volunteers
- 102 people
- Sponsor
- Chiayi Christian Hospital
Resolved Hepatitis B, CD20 Positive B-cell Lymphoma
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
This phase 2 trial aims to evaluate the efficacy of entecavir prophylacxis for hepatitis B virus (HBV) reactivation that continues until 6 months after completing CD20 monoclonal antibody therapy in patients with CD20-positive…
- Trial name
- REHEB (NCT05453435)
- Testing
- Entecavir
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Acute on Chronic Liver Failure
Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.
Data for stool microbiome will be collected for all the chronic hepatitis B subjects (pre cirrhotic,compensated,decompensated and reactivation).
- Trial name
- NCT02689245
- Testing
- Tenofovir, Fecal Microbiota Transplantation (FMT)
- Where
- India
- Volunteers
- 64 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Chronic Hepatitis b, Hepatitis B Reactivation
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
We will conduct a phase 4, multicenter, open-label trial at 8 academic centers in Taiwan. Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir disoproxil fumarate [TDF]) for at least 1 year…
- Trial name
- CHANGE (NCT04496882)
- Testing
- Vemlidy
- Where
- 8 sites in Taiwan
- Volunteers
- 260 people
- Sponsor
- National Taiwan University Hospital
Hiv Infection, Hepatitis B
Descriptive Analysis of Changes in Hepatitis B Markers in People Living With HIV on Injectable Therapy.
In order to assess the risk of hepatitis B reactivation in people living with HIV and undergoing injection therapy, we propose to carry out a descriptive analysis of the evolution of hepatitis B markers in this population.
- Trial name
- NCT06421259
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Occult Hepatitis B Infection in Cancer Patients
Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.
The goal of this observational study is to evalue the cumulative proportion of patients with OBI who do not develop HBsAg seroreversion and/or an increase of serum HBV DNA by at least 1 log above the lower limit of detection of…
- Trial name
- NCT06347588
- Testing
- Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Hepatitis B
Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant
Background: Stem cell transplants (SCTs) are important in treating many diseases. There are two main types of transplants. Autologous stem cells come from the person getting the cells.
- Trial name
- NCT03511794
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma, Chronic Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy
Previous studies dealt with patients who maintained antiviral drugs for 2 ~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral…
- Trial name
- NCT02056548
- Volunteers
- 126 people
- Sponsor
- Seoul St. Mary's Hospital
Chronic Hepatitis C Infection, HBV Coinfection
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
This is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis B virus replication during direct anti-HCV treatment of HCV/HBV co-infection patients.
- Conditions
- Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation
- Trial name
- DASCO (NCT02555943)
- Testing
- Ledipasvir/Sofosbuvir, Sofosbuvir and Daclatasvir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Humanity and Health Research Centre
Chronic Lymphocytic Leukemia
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
This observational retrospective study will enroll at least 158 patients affected by Chronic Lymphoid Leukemia (CLL) with previous HBV exposure (HBsAg negative, anti-HBc positive with or without anti-HBs) treated with Ibrutinib…
- Trial name
- LLC1618 (NCT03528941)
- Testing
- Lamivudine, No prophylaxis
- Where
- 23 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Non-Hodgkin's Lymphoma
Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients
This is a single-arm study. Key eligibility criteria include (1) newly diagnosed, diffuse large B-cell or follicular cell non-Hodgkin's lymphoma; (2) negative test for hepatitis B surface antigen (HBsAg) and positive for antibody…
- Trial name
- NCT00931229
- Testing
- entecavir
- Where
- Taiwan
- Volunteers
- 202 people
- Sponsor
- National Health Research Institutes, Taiwan